Company news
Puretech Health Plc (LSE:PRTC) news
Puretech Health Plc news releases on 6ix. Latest, Aug 13, 2025: PRTC's Vedanta Announces VE202 Phase 2 Results
Press releases — page 2
PRTC's Vedanta Announces VE202 Phase 2 Results
August 13, 2025
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
August 12, 2025
PRTC Launches Celea to Advance Ph3-Ready IPF Drug
August 12, 2025
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
July 17, 2025
PRTC’s Seaport Begins Phase 2b Study in MDD
July 17, 2025
PureTech Announces Leadership Transition
July 16, 2025
PureTech Announces Board Change
July 8, 2025
Directorate Change
July 8, 2025
PDMR Notification
July 4, 2025
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
June 26, 2025
PRTC'S Vor Announces RemeGen License & $175M PIPE
June 26, 2025
PureTech Health: Results of Annual General Meeting
June 16, 2025
Result of AGM
June 16, 2025
PureTech to Present at the Jefferies Global Healthcare Conference
May 22, 2025
PRTC to Present at Jefferies Healthcare Conference
May 22, 2025
PRTC: IPF Data Support Lung Function Stabilization
May 21, 2025
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
May 20, 2025
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
May 9, 2025
PRTC Publishes Research on Unmet IPF Patient Needs
May 9, 2025
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
May 1, 2025
PRTC To Present Ph2b IPF Results at ATS Conference
May 1, 2025
PureTech Announces Annual Results for Year Ended December 31, 2024
April 30, 2025
Final Results
April 30, 2025
PureTech Health: Notice of Results
April 23, 2025
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
April 9, 2025
PRTC Appoints Peel Hunt Joint UK Corporate Broker
April 9, 2025
Rule 2.8 Announcement
April 7, 2025
PureTech Health plc Statement Regarding Press Speculation
April 7, 2025
Statement re Possible Offer
April 7, 2025
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
March 11, 2025
PRTC's Seaport Adds Finance/Operations Exec to BOD
March 11, 2025
PureTech to Present at the Leerink Partners Global Healthcare Conference
February 25, 2025
PRTC Presents at Leerink Partners Healthcare Conf
February 25, 2025
PRTC's Seaport Publishes New Glyph Platform Data
February 12, 2025
PRTC's Vedanta Publishes Ph2 in Nature Medicine
January 27, 2025
PRTC's LYT-200 Gets Fast Track Designation in AML
January 9, 2025
PureTech Appoints UBS as UK Corporate Broker
January 6, 2025
PRTC's Ph2b in IPF Successful; New SOC Potential
December 16, 2024
PRTC's Seaport Presents Ph1 SPT-300 Data at ACNP
December 11, 2024
PRTC Presents LYT-200 Phase 1b Data in AML at ASH
December 9, 2024
PRTC's Seaport Adds Microsoft and J&J Exec to BOD
November 20, 2024
PRTC's Seaport Adds Biotech Finance Exec as CFO
November 5, 2024
Director/PDMR Shareholding
October 31, 2024
PRTC to Present at UBS and Jefferies Conferences
October 30, 2024
PRTC's Seaport Closes $225M Series B Financing
October 21, 2024
PRTC's IPF Patient Research & Ph 2b On Track YE24
October 9, 2024
PRTC to Give 3 Presentations at CHEST 2024 Meeting
October 1, 2024
KarXT/Cobenfy Approved by FDA; PRTC Receives $29M
September 27, 2024
PRTC's Vor Shares New AML Data Validating Approach
September 6, 2024
Results of AGM on 13 June 2024 – Update Statement
August 28, 2024